Recent achievements in the management of Raynaud's phenomenon.
Raynaud's phenomenon is a clinical disorder with episodic digital ischemic vasospasm triggered by cold- or emotional-stress. It was first mentioned by Maurice Raynaud in 1862 describing "a local asphyxia of the extremities" and was further divided into primary Raynaud's disease and secondary Raynaud's phenomenon, which is often related to connective tissue diseases, but also physical or chemical strain. Though pathophysiology of Raynaud's phenomenon is still poorly understood, systemic and local vascular effects are most likely to be involved in primary Raynaud's disease. In secondary Raynaud's phenomenon additional abnormalities in vascular structure and function may play the major role. Thus, medical treatment of Raynaud's phenomenon remains unsatisfactory, due to limited understanding of pathophysiological mechanisms. This review addresses current evidence for medical treatment of primary and secondary Raynaud's phenomenon with regard to pathophysiological mechanisms as well as future perspectives.
Baumhäkel
Magnus
M
Klinik für Innere Medizin III, Kardiologie, Angiologie und Internistische Intensivmedizin, Universitätsklinikum des Saarlandes, Homburg/Saar, Germany. magnus@baumhaekel.de
Böhm
Michael
M
D000317:Adrenergic alpha-Antagonists / Q000627:therapeutic use; D000465:Algorithms; D057911:Angiotensin Receptor Antagonists / Q000627:therapeutic use; D065128:Endothelin Receptor Antagonists; D006801:Humans; D019161:Hydroxymethylglutaryl-CoA Reductase Inhibitors / Q000627:therapeutic use; D011928:Raynaud Disease / Q000209:etiology / Q000503:physiopathology / Q000628:therapy*; D017367:Selective Serotonin Reuptake Inhibitors / Q000627:therapeutic use; D014661:Vasoconstriction / Q000502:physiology; D014664:Vasodilation / Q000502:physiology; D014665:Vasodilator Agents / Q000627:therapeutic use; D054460:rho-Associated Kinases / Q000037:antagonists & inhibitors
D000317:Adrenergic alpha-Antagonists; D057911:Angiotensin Receptor Antagonists; D065128:Endothelin Receptor Antagonists; D019161:Hydroxymethylglutaryl-CoA Reductase Inhibitors; D017367:Selective Serotonin Reuptake Inhibitors; D014665:Vasodilator Agents; D054460:rho-Associated Kinases
J Rheumatol. 2009 Oct;36(10):2264-8
19755613
Clin Res Cardiol. 2008 Jul;97(7):418-31
18454336
Circ Res. 2004 May 28;94(10):1367-74
15087420
Microvasc Res. 2005 May;69(3):178-9
15896360
Haemostasis. 1986;16(1):20-6
2422095
N Engl J Med. 1999 Nov 4;341(19):1447-57
10547409
Am J Respir Crit Care Med. 2005 Jun 1;171(11):1292-7
15750042
Arthritis Rheum. 1999 Dec;42(12):2646-55
10616013
Prog Cardiovasc Dis. 2000 Sep-Oct;43(2):171-96
11014332
Arthritis Rheum. 2004 Jan;50(1):216-26
14730619
Lancet. 1990 Dec 22-29;336(8730):1530-3
1979366
Am J Physiol Heart Circ Physiol. 2000 Apr;278(4):H1075-83
10749700
J Am Acad Dermatol. 2008 Oct;59(4):633-53
18656283
Arthritis Rheum. 2004 Dec;50(12):3985-93
15593188
Lancet. 1982 Jan 9;1(8263):76-7
6119495
Am J Physiol Heart Circ Physiol. 2005 Jul;289(1):H243-50
15764673
Arthritis Rheum. 2003 Jan;48(1):282-3; author reply 283
12528146
J Rheumatol. 2008 Sep;35(9):1830-7
18634152
Clin Exp Rheumatol. 1992 Sep-Oct;10(5):485-8
1458701
Ann Pharmacother. 2006 Nov;40(11):1998-2002
17003081
J Pharmacol Exp Ther. 2008 Dec;327(3):692-8
18812494
Circulation. 1998 Mar 31;97(12):1129-35
9537338
Ann Intern Med. 1994 Feb 1;120(3):199-206
7506013
Clin Res Cardiol. 2006 Feb;95(2):61-7
16598512
Rheumatology (Oxford). 2005 May;44(5):587-96
15741200
Arthritis Rheum. 1995 Jan;38(1):1-4
7818557
Rheumatology (Oxford). 2005 Feb;44(2):145-50
15546967
Rheumatology (Oxford). 2001 Sep;40(9):1038-43
11561116
J Biol Regul Homeost Agents. 2009 Jan-Mar;23(1):23-9
19321043
Am J Med. 1995 Sep;99(3):255-60
7653485
Dev Immunol. 2001;8(3-4):213-21
11785671
J Rheumatol. 2008 Sep;35(9):1801-8
18709692
Circulation. 1951 May;3(5):681-9
14831190
Proc Soc Exp Biol Med. 1999 Sep;221(4):312-25
10460693
Autoimmun Rev. 2008 Oct;8(1):62-8
18692160
Circulation. 2002 Apr 2;105(13):1545-7
11927519
Ann Rheum Dis. 2004 Nov;63(11):1522-4
15479910
Circulation. 2005 Nov 8;112(19):2980-5
16275885
Thromb Haemost. 1988 Oct 31;60(2):141-4
2464198
Arthritis Rheum. 2003 Jul;48(7):1992-2000
12847693
Clin Exp Rheumatol. 2001 Sep-Oct;19(5):503-8
11579708
J Autoimmun. 2001 Feb;16(1):47-58
11221996
Arthritis Rheum. 2004 Dec;50(12):3994-4001
15593189
Expert Rev Cardiovasc Ther. 2005 May;3(3):441-51
15889972
Cochrane Database Syst Rev. 2000;(2):CD000954
10796396
Br J Rheumatol. 1995 Jul;34(7):636-41
7670782
J Pharmacol Exp Ther. 2009 May;329(2):820-6
19193928
Arthritis Rheum. 2004 May;50(5):1578-85
15146428
J Clin Pharmacol. 1982 Jan;22(1):74-6
7037872
Arthritis Rheum. 2001 Aug;44(8):1841-7
11508437
Cochrane Database Syst Rev. 2000;(2):CD000956
10796398
Atherosclerosis. 2009 Dec;207(2):567-72
19717154